ArticleFrontiers in oncology2025
Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- Effect of short-term oral nutrients after hospital discharge on postoperative muscle loss and survival in gastric cancer patients.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemoradiotherapy is a therapeutic approach that prolongs survival but may simultaneously negatively affect the quality of life (QOL) of cancer patients. Current research on quality of life (QOL) in pan-cancer patients undergoing concurrent chemoradiotherapy (CCRT) lacks systematic integration of bibliometric findings with clinical symptom data. Methods: We retrieved 2762 articles from the Web of Science Core Collections. R-bibliometrix, VOSviewer, and CiteSpace were employed to conduct quantitative analysis and visualize research trends and factors influencing QOL. Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified. Results: The included articles were published between 1995 and 2024. The results revealed that the United States and China had the largest number of publications worldwide. Van Berge Henegouwen was the most productive author. The institution leading in this field was the University of Toronto. The International Journal of Radiation Oncology - Biology - Physics was the most productive journal. In addition, keywords with high burst strengths in recent years were 'open label', 'predictor', and 'preoperative chemoradiotherapy'. Tree-ring map of terms related to QOL was visualized and multiple clusters were found, respectively named as "malnutrition", "watch and wait", and so on. Clusters analyses of specific cancers were performed to reveal these unique differences. Finally, among cervical cancer patients, decreased appetite (79.5%), diarrhea (65.8%), and altered taste (59.0%) were the most prevalent symptoms, with three symptom clusters identified. Conclusion: More attention was paid to long-term outcome and patient experience during treatment. Through pan-cancer research and in-depth analysis of specific cancers, we have identified various factors affecting QOL in patients undergoing chemoradiotherapy, including treatment methods, treatment-induced symptoms, psychological factors and so on, enabling us to tailor more personalized treatment plans that improve their overall well-being and enhance QOL during and after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.